Research listings · GLP-1 research listings
Tirzepatide research listings: prices and suppliers
Research materials and consumer products belong to different categories. A listing, laboratory report, or research-use label does not establish suitability for personal use.
We have no commercial relationship with suppliers on this page. Offers are sorted by price per mg; commission never changes the order.
Prices observed weekly · How we check prices →
Tirzepatide listings
No single-substance listings are tracked for Tirzepatide yet.
Research context
From our own records, with the date each was last checked.
- FDA approval
- Approved under NDAs: Mounjaro (first approved 2022-05-13) and Zepbound (2023-11-08)Checked
- 503A / 503B compounding
- Shortage resolved 2024-10-02, confirmed on re-evaluation 2024-12-19; wind-down ended in March 2025 (503A) and on 2025-03-19 (503B); not on the 503B bulks listChecked
- Advisory committee (PCAC)
- Pending editor checkChecked
- Rulemaking / enforcement
- FDA proposed not to include it on the 503B bulks list (notice 2026-05-01; comments extended to 2026-07-30); no final notice found by 2026-10-18Checked
- Human studies
- 1 recorded
- Identity
- Formula C225H348N48O68 · MW 4813 g/mol · CAS 2023788-19-2Source record Checked
Identity noteResearch listings are not Mounjaro or Zepbound. They are not FDA-approved medicines and are not made or checked by the company that makes those products.
How we check prices · Offers are matched to our catalogue by an editor before they appear; a listing is not an endorsement.